Q1 2024 Biostem Technologies Inc Earnings Call Transcript
Key Points
- BioStem Technologies Inc (BSEM) reported a significant increase in first quarter revenue to $41.9 million, up from $600,000 in the same period last year.
- The company achieved a gross margin of 95% in Q1 2024, an improvement from 82% in Q1 2023, indicating enhanced sales strategies and beneficial partnerships.
- BioStem Technologies Inc (BSEM) reported positive net income for the first time on a US GAAP basis, marking a significant financial milestone.
- The company has prioritized examination for a critical patent with the USPTO, enhancing intellectual property protections and distinguishing its products in the market.
- BioStem Technologies Inc (BSEM) successfully completed a rigorous two-year audit, aligning with strategic goals for uplisting to a senior stock exchange, enhancing transparency and regulatory compliance.
- Operating expenses for Q1 2024 increased by $32 million compared to the same period in 2023, primarily due to team expansion and increased service fees.
- Proposed LCDs by Medicare could limit the number of covered products to 15 out of approximately 200, potentially restricting patient access to established products.
- 60% to 80% of the private office volume is currently on the non-covered list, posing challenges in reimbursement and market access.
- The company is still in the process of becoming a fully reporting company with the SEC and applying to a national exchange, indicating ongoing regulatory and administrative tasks.
- BioStem Technologies Inc (BSEM) faces a complex reimbursement landscape that could affect product adoption and market penetration.
Thank you for standing by. My name is Catherine, and I will be your conference operator today. At this time, I would like to welcome everyone to the Biostem Technologies first-quarter 2024 earnings call. (Operator Instructions) Thank you. I would now like to turn the call over to Jeff Ramson, CEO, PCG Advisory. Please go ahead.
Good afternoon, everyone, and thank you for joining our conference call to discuss Biostem's first quarter 2024 financial results and corporate highlights. Leading the call today is Jason Matuszewski, Chief Executive Officer. We're also joined by Mike Fortunato, Chief Financial Officer.
Before we begin I'd like to remind everyone that our remarks today may contain forward-looking statements based on the current expectations of management, which involve inherent risks and uncertainties that could cause actual results to differ materially from those indicated, including the risks and uncertainties described in the company's filings with the over-the-counter market.
You
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
